UNIT 17.7 Screening of Hepatitis C Virus Inhibitors Using Genotype 1a HCV Replicon Cell Lines

  1. Margaret Robinson,
  2. Yang Tian,
  3. Nikos Pagratis,
  4. William E. Delaney IV

Published Online: 1 AUG 2011

DOI: 10.1002/9780471729259.mc1707s22

Current Protocols in Microbiology

Current Protocols in Microbiology

How to Cite

Robinson, M., Tian, Y., Pagratis, N. and Delaney, W. E. 2011. Screening of Hepatitis C Virus Inhibitors Using Genotype 1a HCV Replicon Cell Lines. Current Protocols in Microbiology. 22:17.7:17.7.1–17.7.29.

Author Information

  1. Gilead Sciences, Foster City, California

Publication History

  1. Published Online: 1 AUG 2011
  2. Published Print: AUG 2011


Hepatitis C virus (HCV) replicons are the primary tools for identifying and evaluating anti-HCV compounds during drug discovery research. Genotype 1a and 1b are the most common genotypes in North America and Europe. These genotypes display significant genetic divergence (∼20% at the nucleotide level and ∼14% at the amino acid level), which can translate into marked differences in drug susceptibility. Thus, it is critical that potential therapeutics be assessed against both genotypes to ensure antiviral efficacy in the broad genotype 1 patient population. This unit describes assays for screening HCV inhibitors using replicons with a focus on genotype 1a. Specific protocols are provided for screening 1a replicons that encode the Renilla luciferase gene and for replicons that do not encode exogenous reporter genes, both in 96-well (manual) and in 384-well (high-throughput) formats. Curr. Protoc. Microbiol. 22:17.1.1-17.1.29. © 2011 by John Wiley & Sons, Inc.


  • hepatitis C virus (HCV);
  • genotype 1a;
  • drug screening;
  • replicon